건선약 시장 규모, 점유율, 동향 분석 리포트 : 클래스별, 치료별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Psoriasis Drugs Market Size, Share & Trends Analysis Report By Class, By Treatment (Topicals, Systemic, Biologics), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,176,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,550,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,299,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

건선약 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 건선약 시장 규모는 2030년까지 391억 1,000만 달러에 달할 것으로 추정되며, 2025-2030년에 10.94%의 CAGR로 성장할 전망입니다.

질병에 대한 인식 증가, 생물제제에 대한 상환 전략 증가, 첨단 진단 및 기술 툴이 건선 치료제의 채택을 증가시킬 것으로 예측됩니다.

또한 건선 환자의 저변 확대는 성장 전망을 촉진할 것으로 예측됩니다. 건선의 정확한 원인은 아직 밝혀지지 않았지만, 특정 유전적 및 환경적 요인이 발병을 유발할 수 있습니다. 현재 사용 가능한 대부분의 치료법은 각질세포의 과증식을 억제하여 질병의 진행을 늦추는 것을 목표로 하고 있습니다.

건선은 플라크형, 소반형, 역형, 농포형, 홍반형, 홍피형 등 5가지 유형으로 분류됩니다. 이들 유형은 병변 부위와 병변의 특징에 따라 다릅니다. 홍피형 건선은 가장 드물고, 플라크형 건선은 전 세계 환자들이 앓고 있는 가장 흔한 유형입니다.

건선 발병률은 여러 지역에 걸쳐 수년간 서서히 증가하고 있습니다. 이러한 증가는 생활습관의 변화뿐만 아니라 유전적, 환경적 요인에 기인하는 것으로 추정됩니다. 유병률 증가는 또한 질병 조절을 위한 치료에 대한 반응성 저하 및 내성 발달과 관련이 있을 수 있습니다.

건선 치료제 시장 보고서 하이라이트

• 종양 괴사 인자 억제제가 시장을 장악하고 2024년에는 40.88%의 점유율을 차지합니다.
• 생물제제 부문은 건선과 관련된 특정 면역 경로에 대한 선택성이 높고, 기존 의약품에 비해 질병 관리가 크게 개선되며, 2024년 46.38%의 점유율을 차지하며 시장을 장악할 것으로 예측됩니다.
• 국소 투여 부문은 예측 기간 중 큰 성장률을 나타낼 것으로 예측됩니다.
• 비경구약 부문은 시장을 독점하며, 2024년에는 41.58%의 점유율을 차지합니다.
• 병원 약국 부문은 2024년 건선 치료제 산업의 주요 점유율을 차지합니다.
• 북미 건선 치료제 시장은 2024년 세계 점유율의 38.65%를 차지하며 시장 선두를 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 건선약 시장의 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 건선약 시장 : 클래스별 비즈니스 분석

• 클래스별 시장 점유율, 2025년과 2030년
• 클래스별 부문 대시보드
• 시장 규모, 예측, 동향 분석(클래스별, 2018-2030년)
• 종양괴사인자 저해제
• 인터류킨 저해제
• 비타민 D 유사체
• 코르티코스테로이드
• 기타

제5장 건선약 시장 : 치료별 비즈니스 분석

• 치료별 시장 점유율, 2025년과 2030년
• 치료별 부문 대시보드
• 시장 규모와 예측 및 동향 분석(치료별, 2018-2030년)
• 외용약
• 전신적
• 생물제제

제6장 건선약 시장 : 투여 경로별 비즈니스 분석

• 투여 경로별 시장 점유율, 2025년과 2030년
• 투여 경로별 부문 대시보드
• 시장 규모, 예측, 동향 분석(투여 경로별, 2018-2030년)
• 경구
• 비경구
• 외용

제7장 건선약 시장 : 유통 채널별 비즈니스 분석

• 유통 채널별 시장 점유율, 2025년과 2030년
• 유통 채널별 부문 대시보드
• 시장 규모, 예측, 동향 분석(유통 채널별, 2018-2030년)
• 병원 약국
• 소매 약국
• 기타 약국

제8장 건선약 시장 : 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2025년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 참가자 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/상장기업
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson &Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Celgene Corporation
  • UCB SA
  • Merck
  • Boehringer Ingelheim International GmbH

KSA

영문 목차

영문목차

Psoriasis Drugs Market Growth & Trends:

The global psoriasis drugs market size is estimated to reach USD 39.11 billion by 2030, registering to grow at a CAGR of 10.94% from 2025 to 2030 according to a new report by Grand View Research, Inc. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Psoriasis Drugs Market Report Highlights:

• Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.88% in 2024 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
• The biologics segment dominated the market in 2024 with a share of 46.38% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
• The topical segment is expected to register a significant growth rate over the forecast period.
• The parenteral segment dominated the market, accounting for a 41.58% share in 2024.
• The hospital pharmacies segment accounted for a leading share of the psoriasis drugs industry in 2024.
• North America psoriasis drugs market held a leading market position in 2024, accounting for 38.65% of the global share.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Class
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Psoriasis Drug Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Psoriasis Drug Market: Class Business Analysis

• 4.1. Class Market Share, 2025 & 2030
• 4.2. Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Class, 2018 to 2030 (USD Million)
• 4.4. Tumor Necrosos Factor Inhibitors
  • 4.4.1. Tumor Necrosos Factor Inhibitors Market, 2018 - 2030 (USD Million)
• 4.5. Interleukin Inhibitors
  • 4.5.1. Interleukin Inhibitors Market, 2018 - 2030 (USD Million)
• 4.6. Vitamin D Analogues
  • 4.6.1. Vitamin D Analogues Market, 2018 - 2030 (USD Million)
• 4.7. Corticosteroids
  • 4.7.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Other Class Market, 2018 - 2030 (USD Million)

Chapter 5. Psoriasis Drug Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2025 & 2030
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 5.4. Topicals
  • 5.4.1. Topicals Market, 2018 - 2030 (USD Million)
• 5.5. Systemic
  • 5.5.1. Systemic Market, 2018 - 2030 (USD Million)
• 5.6. Biologics
  • 5.6.1. Biologics Market, 2018 - 2030 (USD Million)

Chapter 6. Psoriasis Drug Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Parental
  • 6.5.1. Parental Market, 2018 - 2030 (USD Million)
• 6.6. Topical
  • 6.6.1. Tropical Market, 2018 - 2030 (USD Million)

Chapter 7. Psoriasis Drug Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Other Pharmacies
  • 7.6.1. Others Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Psoriasis Drug Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Psoriasis Drug Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Psoriasis Drug Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Amgen Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Johnson & Johnson Services, Inc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Novartis AG
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Eli Lilly and Company
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AstraZeneca
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Celgene Corporation
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. UCB S.A.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Merck
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Boehringer Ingelheim International GmbH
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives

관련자료